TY - JOUR
T1 - Diuretics in States of Volume Overload
T2 - Core Curriculum 2022
AU - Novak, James E.
AU - Ellison, David H.
N1 - Funding Information:
James E. Novak, MD, PhD, and David H. Ellison, MD. None. The authors declare that they have no relevant financial interests. Received August 6, 2021, in response to an invitation from the journal. Evaluated by 2 external peer reviewers and a member of the Feature Advisory Board, with direct editorial input from the Feature Editor and a Deputy Editor. Accepted in revised form September 29, 2021.
Publisher Copyright:
© 2021 National Kidney Foundation, Inc.
PY - 2022/8
Y1 - 2022/8
N2 - Volume overload, defined as excess total body sodium and water with expansion of extracellular fluid volume, characterizes common disorders such as congestive heart failure, end-stage liver disease, chronic kidney disease, and nephrotic syndrome. Diuretics are the cornerstone of therapy for volume overload and comprise several classes whose mechanisms of action, pharmacokinetics, indications, and adverse effects are essential principles of nephrology. Loop diuretics are typically the first-line treatment in the management of hypervolemia, with additional drug classes indicated in cases of diuretic resistance and electrolyte or acid-base disorders. Separately, clinical trials highlight improved outcomes in some states of volume overload, such as loop diuretics and sodium/glucose cotransporter 2 inhibitors in patients with congestive heart failure. Resistance to diuretics is a frequent, multifactorial clinical challenge that requires creative and physiology-based solutions. In this installment of AJKD's Core Curriculum in Nephrology, we discuss the pharmacology and therapeutic use of diuretics in states of volume overload and strategies to overcome diuretic resistance.
AB - Volume overload, defined as excess total body sodium and water with expansion of extracellular fluid volume, characterizes common disorders such as congestive heart failure, end-stage liver disease, chronic kidney disease, and nephrotic syndrome. Diuretics are the cornerstone of therapy for volume overload and comprise several classes whose mechanisms of action, pharmacokinetics, indications, and adverse effects are essential principles of nephrology. Loop diuretics are typically the first-line treatment in the management of hypervolemia, with additional drug classes indicated in cases of diuretic resistance and electrolyte or acid-base disorders. Separately, clinical trials highlight improved outcomes in some states of volume overload, such as loop diuretics and sodium/glucose cotransporter 2 inhibitors in patients with congestive heart failure. Resistance to diuretics is a frequent, multifactorial clinical challenge that requires creative and physiology-based solutions. In this installment of AJKD's Core Curriculum in Nephrology, we discuss the pharmacology and therapeutic use of diuretics in states of volume overload and strategies to overcome diuretic resistance.
KW - Volume overload
KW - carbonic anhydrase inhibitor (CAI)
KW - chronic kidney disease (CKD)
KW - diuretic resistance
KW - end-stage liver disease (ESLD)
KW - furosemide
KW - heart failure (HF)
KW - loop diuretics
KW - nephrotic syndrome (NS)
KW - osmotic diuretic
KW - review
KW - sodium/glucose cotransporter 2 inhibitor (SGLT2i)
KW - sulfonamide
KW - thiazide
KW - vasopressin receptor antagonists
UR - http://www.scopus.com/inward/record.url?scp=85124892592&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124892592&partnerID=8YFLogxK
U2 - 10.1053/j.ajkd.2021.09.029
DO - 10.1053/j.ajkd.2021.09.029
M3 - Review article
C2 - 35190215
AN - SCOPUS:85124892592
SN - 0272-6386
VL - 80
SP - 264
EP - 276
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
IS - 2
ER -